Corneal Copper Deposition Secondary to Oral Contraceptives

Optometry and Vision Science

Volumn 85, Issue 9, 2008, Pages E802-E807

  Garmizo, Gustavo ^a   Frauens, Barry J ^a  

^a West Broward Eye Care Associates   (United States)

Author keywords

Ceruloplasmin; Copper toxicity; Corneal pigment ring; Estrogen; Hepatolenticular degeneration; Hypercupremia; Kayser Fleischer ring; Oral contraceptives; Progesterone; Serum copper; Side effect; Wilson s disease

Indexed keywords

ALDOSTERONE ANTAGONIST; ANDROSTANE DERIVATIVE; CERULOPLASMIN; COPPER; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVOTHYROXINE; LEVOTHYROXINE SODIUM;

ADULT; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; CORNEA DISEASE; DESCEMET MEMBRANE; DRUG EFFECT; FEMALE; HUMAN; PATHOLOGY; PIGMENT DISORDER; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CERULOPLASMIN BLOOD LEVEL; CONFERENCE PAPER; CONTACT LENS; COPPER BLOOD LEVEL; CORNEA PIGMENT RING; EYE EXAMINATION; HORMONE SUBSTITUTION; HYPERCUPREMIA; MENOPAUSAL SYNDROME; ORAL CONTRACEPTION; PRESCRIPTION; PRIORITY JOURNAL; SLIT LAMP; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; WILSON DISEASE;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CERULOPLASMIN; CONTRACEPTIVES, ORAL; COPPER; CORNEAL DISEASES; DESCEMET MEMBRANE; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; PIGMENTATION DISORDERS;

CERULOPLASMIN; COPPER TOXICITY; CORNEAL PIGMENT RING; ESTROGEN; HEPATOLENTICULAR DEGENERATION; HYPERCUPREMIA; KAYSER-FLEISCHER RING; ORAL CONTRACEPTIVES; PROGESTERONE; SERUM COPPER; SIDE EFFECT; WILSON'S DISEASE;

BODY FLUIDS; COPPER; COPPER COMPOUNDS; DEPOSITS; TOXICITY;

COPPER DEPOSITS;

EID: 58149121622     PISSN: 10405488     EISSN: 15389235     Source Type: Journal    
DOI: 10.1097/OPX.0b013e3181853092     Document Type: Article

References (89)

1. Louro MO, Cocho JA, Tutor JC. Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin. Clin Chim Acta 2001;312:123-7.
2. Vir SC, Love AH, Thompson W. Serum and hair concentrations of copper during pregnancy. Am J Clin Nutr 1981;34:2382-8.
3. Dokumov SI. Serum copper and pregnancy. Am J Obstet Gynecol 1968;101:217-22.
4. Burrows S, Pekala B. Serum copper and ceruloplasmin in pregnancy. Am J Obstet Gynecol 1971;109:907-9.
5. Ozgunes H, Beksac MS, Duru S, Kayakirilmaz K. Instant effect of induced abortion on serum ceruloplasmin activity, copper and zinc levels. Arch Gynecol 1987;240:21-5.
6. Reinhold JG. Trace elements—a selective survey. Clin Chem 1975;21:476-500.
7. Lahey ME, Gubler CJ, Cartwright GE, Wintrobe MM. Studies on copper metabolism. VII. Blood copper in pregnancy and various pathologic states. J Clin Invest 1953;32:329-39.
8. Cartwright GE, Gubler CJ, Wintrobe MM. Studies on copper metabolism. XI. Copper and iron metabolism in the nephrotic syndrome. J Clin Invest 1954;33:685-98.
9. Schwartz MK. Role of trace elements in cancer. Cancer Res 1975;35:3481-7.
10. Wintrobe M. Copper in health and disease. Am J Clin Nutr 1957;6:75-6.
11. Sondheimer JH, Mahajan SK, Rye DL, Abu-Hamdan DK, Migdal SD, Prasad AS, McDonald FD. Elevated plasma copper in chronic renal failure. Am J Clin Nutr 1988;47:896-9.
12. Vaidya SM, Kamalakar PL. Copper and ceruloplasmin levels in serum of women with breast cancer. Indian J Med Sci 1998;52:184-7.
13. Ellis PP. Ocular deposition of copper in hypercupremia. Am J Ophthalmol 1969;68:423-7.
14. Hrgovcic M, Tessmer CF, Thomas FB, Fuller LM, Gamble JF, Shullenberger CC. Significance of serum copper levels in adult patients with Hodgkin’s disease. Cancer 1973;31:1337-45.
15. Faryadi M, Mohebali M. Alterations of serum zinc, copper, and iron concentrations in patients with acute and chronic leishmaniasis. Iranian J Pub Heal 2003;32:53-8.
16. Carruthers ME, Hobbs CB, Warren RL. Raised serum copper and caeruloplasmin levels in subjects taking oral contraceptives. J Clin Pathol 1966;19:498-500.
17. Rubinfeld Y, Maor Y, Simon D, Modai D. A progressive rise in serum copper levels in women taking oral contraceptives: a potential hazard? Fertil Steril 1979;32:599-601.
18. Horwitt MK, Harvey CC, Dahm CH Jr. Relationship between levels of blood lipids, vitamins C, A, and E, serum copper compounds, and urinary excretions of tryptophan metabolites in women taking oral contraceptive therapy. Am J Clin Nutr 1975;28:403-12.
19. Lei KY, Prasad AS, Bowersox E, Oberleas D. Oral contraceptives, norethindrone and mestranol: effects on tissue levels of minerals. Am J Physiol 1976;231:98-103.
20. Meram I, Balat O, Tamer L, Ugur MG. Trace elements and vitamin levels in menopausal women receiving hormone replacement therapy. Clin Exp Obstet Gynecol 2003;30:32-4.
21. Berg G, Kohlmeier L, Brenner H. Effect of oral contraceptive progestins on serum copper concentration. Eur J Clin Nutr 1998;52:711-15.
22. Akhter S, Shamsuzzaman AK, Banarjee M, Seema SA, Deb K. Serum copper in rural women taking combined oral contraceptive. Mymensingh Med J 2006;15:25-9.
23. McMaster D, McCrum E, Patterson CC, Kerr MM, O’Reilly D, Evans AE, Love AH. Serum copper and zinc in random samples of the population of Northern Ireland. Am J Clin Nutr 1992;56:440-6.
24. Newhouse IJ, Clement DB, Lai C. Effects of iron supplementation and discontinuation on serum copper, zinc, calcium, and magnesium levels in women. Med Sci Sports Exerc 1993;25:562-71.
25. Kayser B. Uber einen Fall von angeborener grunlicher Verfarbung des Cornea. Kinishe Monatsblatter Fur Augenheikunde 1902;40:22-5.
26. Fleischer B. Zwei weitere Falle von grunlicher Verfarbung ser Kornea. Kinishe Monatsblatter Fur Augenheikunde 1903;41:489-91.
27. Oracz G, Klimczak-Slaczka D, Sokolowska-Oracz A, Socha P, Gralek M, Szaflik J, Dadalski M. [Prevalence of Kayser-Fleischer ring in patients with Wilson’s disease]. Klin Oczna 2005;107:54-6.
28. Liu M, Cohen EJ, Brewer GJ, Laibson PR. Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol 2002;133:832-4.
29. Datta S, Datta H. Kayser-Fleischer ring. Indian Pediatr 2004;41:744.
30. Harry J, Tripathi R. The Kayser Fleischer ring. Trans Ophthalmol Soc U K 1970;90:191-3.
31. Harry J, Tripathi R. Kayser-Fleischer ring. A pathological study. Br J Ophthalmol 1970;54:794-800.
32. Wiebers DO, Hollenhorst RW, Goldstein NP. The ophthalmologic manifestations of Wilson’s disease. Mayo Clin Proc 1977;52:409-16.
33. Tso MO, Fine BS, Thorpe HE. Kayser-Fleischer ring and associated cataract in Wilson’s disease. Am J Ophthalmol 1975;79:479-88.
34. Palmer GB. A case of Wilson’s disease with Kayser Fleischer ring. N Z Med J 1951;50:56-7.
35. Sullivan CA, Chopdar A, Shun-Shin GA. Dense Kayser-Fleischer ring in asymptomatic Wilson’s disease (hepatolenticular degeneration). Br J Ophthalmol 2002;86:114.
36. Rodman R, Burnstine M, Esmaeli B, Sugar A, Martonyi C, Johnson V, Brewer G. Wilson’s disease: presymptomatic patients and Kayser-Fleischer rings. Ophthalmic Genet 1997;18:79-85.
37. Uzman LL, Jakus MA. The Kayser-Fleischer ring: a histochemical and electron microscope study. Neurology 1957;7:341-55.
38. Frommer D, Morris J, Sherlock S, Abrams J, Newman S. Kayser-Fleischer-like rings in patients without Wilson’s disease. Gastroenterology 1977;72:1331-5.
39. Fleming CR, Dickson ER, Wahner HW, Hollenhorst RW, McCall JT. Pigmented corneal rings in non-Wilsonian liver disease. Ann Intern Med 1977;86:285-8.
40. Hawkins AS, Stein RM, Gaines BI, Deutsch TA. Ocular deposition of copper associated with multiple myeloma. Am J Ophthalmol 2001;131:257-9.
41. Martin NF, Kincaid MC, Stark WJ, Petty BG, Surer JL, Hirst LW, Green WR. Ocular copper deposition associated with pulmonary carcinoma, IgG monoclonal gammopathy and hypercupremia. A clinicopathologic correlation. Ophthalmology 1983;90:110-16.
42. Probst LE, Hoffman E, Cherian MG, Yang J, Feagan B, Adams P, Nichols B. Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia. Cornea 1996;15:94-8.
43. Aldave AJ, King JA, Kim BT, Hopp L. Corneal copper deposition associated with chronic lymphocytic leukemia. Am J Ophthalmol 2006;142:174-6.
44. Mitchell AM, Heller GL. Changes in Kayser-Fleischer ring during treatment of hepatolenticular degeneration. Arch Ophthalmol 1968;80:622-31.
45. Innes JR, Strachan IM, Triger DR. Unilateral Kayser-Fleischer ring. Br J Ophthalmol 1986;70:469-70.
46. Hiti H, Harpf H, Wutz W, Schmut O. [Regression of a Kayser-Fleischer ring in a case of Wilson’s disease during penicillamine therapy (author’s transl)]. Klin Monatsbl Augenheilkd 1980;176:235-8.
47. Esmaeli B, Burnstine MA, Martonyi CL, Sugar A, Johnson V, Brewer GJ. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson’s disease. Cornea 1996;15:582-8.
48. Lossner A, Lossner J, Bachmann H, Zotter J. The Kayser-Fleischer ring during long-term treatment in Wilson’s disease (hepatolenticular degeneration). A follow-up study. Graefes Arch Clin Exp Ophthalmol 1986;224:152-5.
49. Sussman W, Scheinberg IH. Disappearance of Kayser-Fleischer rings. Effects of penicillamine. Arch Ophthalmol 1969;82:738-41.
50. Johnson RE, Campbell RJ. Wilson’s disease. Electron microscopic, x-ray energy spectroscopic, and atomic absorption spectroscopic studies of corneal copper deposition and distribution. Lab Invest 1982;46:564-9.
51. Johnson BL. Ultrastructure of the Kayser-Fleischer ring. Am J Ophthalmol 1973;76:455-61.
52. Belkin M, Zeimer R, Chajek T, Friedman G, Melamed E. Non-invasive quantitation of corneal copper in hepatolenticular degeneration (Wilson’s disease). Lancet 1976;1:391-2.
53. Obara H, Ikoma N, Sasaki K, Tachi K. Usefulness of Scheimpflug photography to follow up Wilson’s disease. Ophthalmic Res 1995;27(suppl 1):100-3.
54. Schoenberger M, Ellis PP. Disappearance of Kayser-Fleischer rings after liver transplantation. Arch Ophthalmol 1979;97:1914-15.
55. Lipman RM, Deutsch TA. A yellow-green posterior limbal ring in a patient who does not have Wilson’s disease. Arch Ophthalmol 1990;108:1385.
56. Rahmani B, Jampol LM, Feder RS. Clinicopathologic reports, case reports, and small case series: peripheral pigmented corneal ring: a new finding in hypercarotenemia. Arch Ophthalmol 2003;121:403-7.
57. Kincaid MC, Green WR, Hoover RE, Schenck PH. Ocular chrysiasis. Arch Ophthalmol 1982;100:1791-4.
58. Kumar N, Butz JA, Burritt MF. Clinical significance of the laboratory determination of low serum copper in adults. Clin Chem Lab Med 2007;45:1402-10.
59. Ferenci P. Wilson’s disease. Clin Liver Dis 1998;2:31-49.
60. Pfeil SA, Lynn DJ. Wilson’s disease: copper unfettered. J Clin Gastroenterol 1999;29:22-31.
61. Frommer DJ. Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion 1981;21:169-78.
62. Evans GW, Bubois RS, Hambidge KM. Wilson’s disease: identification of an abnormal copper-binding protein. Science 1973;181:1175-6.
63. Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson’s disease: an experience over three decades. Gut 2000;46:415-19.
64. Schilsky ML. Diagnosis and treatment of Wilson’s disease. Pediatr Transplant 2002;6:15-19.
65. Ferenci P. Review article: diagnosis and current therapy of Wilson’s disease. Aliment Pharmacol Ther 2004;19:157-65.
66. Castellano G, Blasco A, Ballesta F, Colina F, Moreno D, Franch O, Urruzuno P, Solis JA. [Wilson’s disease. A retrospective analysis of 12 cases]. Rev Clin Esp 1992;190:223-8.
67. Gunther P, Hermann W, Kuhn HJ, Wagner A. [Wilson’s disease]. Ther Umsch 2007;64:57-61.
68. Gao WS, Liu YW, Chen J. [Analysis of 128 Wilson’s disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001;23:506-8.
69. Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology 1996;46:1040-3.
70. Roberts EA. Wilson’s disease: a new direction. Saudi J Gastroenterol 1995;1:163-8.
71. Tissieres P, Chevret L, Debray D, Devictor D. Fulminant Wilson’s disease in children: appraisal of a critical diagnosis. Pediatr Crit Care Med 2003;4:338-43.
72. Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P. Screening for Wilson’s disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997;27:358-62.
73. Merli M, Patriarca M, Loudianos G, Valente C, Riggio O, De Felice G, Petrucci F, Caroli S, Attili AF. Use of the stable isotope 65Cu test for the screening of Wilson’s disease in a family with two affected members. Ital J Gastroenterol Hepatol 1998;30:270-5.
74. Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson’s disease. Methods in pathology. Am J Clin Pathol 1994;102:443-6.
75. Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson’s disease. Hepatology 1992;15:609-15.
76. Mak CM, Tam S, Fan ST, Liu CL, Lam CW. Wilson’s disease: a patient undiagnosed for 18 years. Hong Kong Med J 2006;12:154-8.
77. Xu P, Liang X, Jankovic J, Le W. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol 2001;58:1879-82.
78. Nanji MS, Nguyen VT, Kawasoe JH, Inui K, Endo F, Nakajima T, Anezaki T, Cox DW. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997;60:1423-9.
79. Wu ZY, Lin MT, Murong SX, Wang N. Molecular diagnosis and prophylactic therapy for presymptomatic Chinese patients with Wilson disease. Arch Neurol 2003;60:737-41.
80. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006;120:151-9.
81. Brito JC, Coutinho Mde A, Almeida HJ, Nobrega PV. [Wilson’s disease: clinical diagnosis and “faces of panda” signs in magnetic resonance imaging. Case report]. Arq Neuropsiquiatr 2005;63:176-9.
82. van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531-6.
83. Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H. Cranial MRI in Wilson’s disease. Neuroradiology 1990;32:211-14.
84. Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, Vasudev MK, Swamy HS. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48:613-21.
85. Kim TJ, Kim IO, Kim WS, Cheon JE, Moon SG, Kwon JW, Seo JK, Yeon KM. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol 2006;27:1373-8.
86. King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA. Cranial MR imaging in Wilson’s disease. AJR Am J Roentgenol 1996;167:1579-84.
87. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry (ATDRS). Toxicological profile for copper; CAS: 7440-50-8, September 4, 2004. Available at: http://www.atsdr.cdc.gov/toxprofiles/tp132.pdf. Accessed May 28, 2008.
88. Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol 2000;151:1182-8.
89. Leone N, Courbon D, Ducimetiere P, Zureik M. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology 2006;17:308-14.